TTPH - Tetraphase Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.34
-0.28 (-7.73%)
At close: 4:00PM EDT

3.34 0.00 (0.00%)
After hours: 4:21PM EDT

Stock chart is not supported by your current browser
Previous Close3.62
Open3.64
Bid3.20 x 900
Ask3.62 x 800
Day's Range3.15 - 3.65
52 Week Range2.05 - 8.75
Volume1,654,000
Avg. Volume626,657
Market Cap172.444M
Beta3.74
PE Ratio (TTM)N/A
EPS (TTM)-2.26
Earnings DateJul 31, 2018 - Aug 6, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Tetraphase Pharmaceuticals Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    Tetraphase Pharmaceuticals, Inc. (TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that Tetraphase's Compensation Committee of the Board of Directors approved, pursuant to NASDAQ Listing Rule 5635(c)(4), the grant of inducement equity awards in the form of stock options to four new employees to purchase an aggregate of 60,000 shares of Tetraphase's common stock. The options were granted as an inducement equity awards outside Tetraphase's 2013 Stock Incentive Plan and were made as an inducement material to four new employee’s acceptance of employment with Tetraphase. The stock options have exercise prices equal to the closing price of Tetraphase's common stock on July 13, 2018.

  • ACCESSWIRE4 days ago

    Breakfast Technical Briefing on Tetraphase Pharma and Three Other Additional Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 12, 2018 / If you want a free Stock Review on TTPH sign up now at www.wallstequities.com/registration. Companies in the Biotechnology industry primarily use living organisms or molecular and cellular techniques to provide chemicals, food, and services that meet human needs.

  • GlobeNewswire25 days ago

    Detailed Research: Economic Perspectives on Tetraphase Pharmaceuticals, Tech Data, Southern National Bancorp of Virginia, Esterline Technologies, Myers Industries, and Hersha Hospitality Trust — What Drives Growth in Today's Competitive Landscape

    NEW YORK, June 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tetraphase ...

  • GlobeNewswirelast month

    Tetraphase Pharmaceuticals Announces Data from a Pooled Analysis of IGNITE1 and IGNITE4 Phase 3 Trials Evaluating Eravacycline in Complicated Intra-Abdominal Infections at the ASM Microbe 2018 Annual Meeting

    Tetraphase Pharmaceuticals, Inc. (TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, recently reported data on eravacycline, which is currently under review by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of complicated intra-abdominal infections (cIAI), as well as data for TP-6076, its second-generation candidate targeting MDR Gram-negative bacteria, which is currently in phase 1 clinical testing. “For the first time, we are sharing a pooled analysis of our IGNITE1 and IGNITE4 studies of eravacycline and are pleased to show that favorable clinical and microbiological responses were observed for eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including those demonstrating resistant phenotypes and genotypes such as MDR and extended spectrum beta-lactamase (ESBL) production,” said Guy Macdonald, President and Chief Executive Officer of Tetraphase.

  • GlobeNewswirelast month

    Tetraphase Pharmaceuticals Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    Tetraphase Pharmaceuticals, Inc. (TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that Tetraphase's Compensation Committee of the Board of Directors approved, pursuant to NASDAQ Listing Rule 5635(c)(4), the grant of inducement equity awards in the form of stock options to four new employees to purchase an aggregate of 60,000 shares of Tetraphase's common stock. The options were granted as an inducement equity awards outside Tetraphase's 2013 Stock Incentive Plan and were made as an inducement material to eight new employee’s acceptance of employment with Tetraphase. The stock options have exercise prices equal to the closing price of Tetraphase's common stock on June 15, 2018.

  • ACCESSWIRElast month

    Today's Free Research Reports Coverage on Seattle Genetics and Three More Biotech Stocks

    On Wednesday, June 06, 2018, US markets saw broad based gains with eight out of nine sectors finishing the trading sessions in green. All you have to do is sign up today for this free limited time offer by clicking the link below.

  • Reuterslast month

    BRIEF-Tetraphase Pharmaceuticals Announces Everest Medicines’ Submission Of Drug Application For Eravacycline In Complicated Intra-Abdominal Infection To The China FDA

    June 4 (Reuters) - Tetraphase Pharmaceuticals Inc: * TETRAPHASE PHARMACEUTICALS ANNOUNCES EVEREST MEDICINES’ SUBMISSION OF AN INVESTIGATIONAL NEW DRUG APPLICATION FOR ERAVACYCLINE IN COMPLICATED INTRA-ABDOMINAL ...

  • GlobeNewswirelast month

    Tetraphase Pharmaceuticals Announces Everest Medicines’ Submission of an Investigational New Drug Application for Eravacycline in Complicated Intra-Abdominal Infection to the China Food and Drug Administration

    Tetraphase Pharmaceuticals, Inc. (TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that Everest Medicines Limited (“Everest”), a C-Bridge Capital-backed biopharmaceutical company based in China which has the exclusive license to develop and commercialize eravacycline in China, Taiwan, Hong Kong, Macau, South Korea and Singapore (the “Territories”), has submitted an Investigational New Drug (IND) application to China's Food and Drug Administration (CFDA) for a phase 3 clinical trial of eravacycline in complicated intra-abdominal infections (cIAI).

  • GlobeNewswire2 months ago

    Tetraphase Pharmaceuticals to Present Eravacycline and TP-6076 Data at ASM Microbe 2018

    –Four Abstracts Selected for Poster Presentations–. –Presentations Include New Eravacycline Pooled Analysis of IGNITE 1 and IGNITE4 and Data Highlighting the Pre-Clinical Activity of TP-6076–. WATERTOWN, ...

  • GlobeNewswire2 months ago

    Tetraphase Pharmaceuticals to Present at the UBS Global Healthcare Conference

    WATERTOWN, Mass., May 09, 2018-- Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant infections, announced today that ...

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Tetraphase Pharmaceuticals and Medtronic

    NEW YORK, NY / ACCESSWIRE / May 8, 2018 / Shares of medical stocks Tetraphase Pharamceuticals and Medtronic both saw gains on Monday. Shares of Medtronic shares soared after it was announced that J.P. Morgan Chase & Co. managing director Mike Weinstein has joined the company.

  • Associated Press2 months ago

    Tetraphase: 1Q Earnings Snapshot

    The Watertown, Massachusetts-based company said it had a loss of 42 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire2 months ago

    Tetraphase Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Highlights

    Tetraphase Pharmaceuticals, Inc. (TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the first quarter ended March 31, 2018. “During the first quarter, we revised our eravacycline strategy to focus primarily on the commercialization of the IV formulation of the drug in complicated intra-abdominal infections (cIAI), for which we have submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) based on the positive results of the IGNITE1 and IGNITE4 phase 3 clinical trials,” said Guy Macdonald, President and Chief Executive Officer of Tetraphase. “We recently presented data from IGNITE4, in which eravacycline demonstrated statistical non-inferiority to meropenem, at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).

  • GlobeNewswire3 months ago

    Recent Analysis Shows Morningstar, Tactile Systems Technology, Allete, Tetraphase Pharmaceuticals, Magellan Health, and Ambarella Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, April 30, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • Analysts’ Ratings for Sarepta Therapeutics and Peers in April
    Market Realist3 months ago

    Analysts’ Ratings for Sarepta Therapeutics and Peers in April

    How Is Sarepta Therapeutics Positioned in 2018? Sarepta Therapeutics (SRPT) is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics, gene therapy, and other genetic approaches for treating rare neuromuscular diseases. Of the 19 analysts covering Sarepta Therapeutics in April 2018, six analysts gave the stock a “strong buy” rating, 11 analysts gave it a “buy” rating, and two analysts gave it a “hold” rating.

  • Tetraphase Pharmaceuticals’ Cash Flow and Price Performance
    Market Realist3 months ago

    Tetraphase Pharmaceuticals’ Cash Flow and Price Performance

    Tetraphase Pharmaceuticals (TTPH) posted $98.0 million in operating expenses in fiscal 2017, compared with $63.7 million in fiscal 2016. This $34.3 million rise resulted from increased expenses related to the company’s eravacycline Phase 3 studies. Other primary factors included higher drug manufacturing and nonclinical costs in support of its New Drug Application (or NDA) and precommercialization activities for eravacycline.

  • GlobeNewswire3 months ago

    Tetraphase Pharmaceuticals to Present Data at the 38th Annual Meeting of the Surgical Infection Society

    Tetraphase Pharmaceuticals, Inc. (TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced two data presentations at the 38th Annual Meeting of the Surgical Infection Society (SIS), taking place April 22-25, at the Four Seasons in Westlake Village, CA. Presentations will include information about the Company’s lead drug candidate, eravacycline, which is in development for the treatment of complicated intra-abdominal infections (cIAI). “Data presented at SIS’s Annual Meeting demonstrate eravacycline’s potent in vitro activity from a total of 7,815 single-patient clinical isolates collected during a four-year period from U.S. hospitals,” said Guy Macdonald, President and Chief Executive Officer of Tetraphase Pharmaceuticals.

  • Exploring Tetraphase Pharmaceuticals’ Financial Performance
    Market Realist3 months ago

    Exploring Tetraphase Pharmaceuticals’ Financial Performance

    Tetraphase Pharmaceuticals (TTPH) generated contract and grant revenues of $9.6 million in fiscal 2017 compared with $5.1 million in fiscal 2016. Until now, the primary source of revenues for the company has been US government contracts. 

  • A Look at Tetraphase Pharmaceuticals’ Target Market
    Market Realist3 months ago

    A Look at Tetraphase Pharmaceuticals’ Target Market

    Tetraphase Pharmaceuticals (TTPH) is developing eravacycline, a fully synthetic flurocycline for use as a first-line empiric monotherapy for treating multidrug-resistant infections. These infections include gram-negative infections such as those found in complicated intra-abdominal infections (or cIAL).

  • How Analysts View Tetraphase Pharmaceuticals in April 2018
    Market Realist3 months ago

    How Analysts View Tetraphase Pharmaceuticals in April 2018

    Tetraphase Pharmaceuticals (TTPH) is a clinical-stage biopharmaceutical company focused on creating novel antibiotics. These antibiotics treat serious and life-threatening multidrug-resistant infections by using the company’s proprietary chemistry technology. Its lead product candidate is eravacycline, which is being developed as an intravenous antibiotic.

  • ACCESSWIRE3 months ago

    Blog Exposure - Tetraphase Pharma Announced Data Presentations from IGNITE4 Study at 28th European Congress of Clinical Microbiology and Infectious Diseases

    Stock Monitor: Akari Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 16, 2018 / Active-Investors.com has just released a free research report on Tetraphase Pharma, Inc. (NASDAQ: TTPH ...

  • Top High Growth NasdaqCM Stocks This Month
    Simply Wall St.3 months ago

    Top High Growth NasdaqCM Stocks This Month

    Why invest in a stock whose growth outlook that lags behind the market? Investors looking for companies with extraordinary future prospects in terms of profitability and returns should look atRead More...